Publishing on December 15, 2022 at 2:00 pm local time (EEST)

Biohit Oyj’s R&D Director PhD and Associate Professor Minna Mäki has resigned. Current Head of Technical Product Management Panu Hendolin has been appointed to new R&D Director.

Hendolin has worked at Biohit as R&D and Production Director in 2007-2008, as well as 2012-2017, and he returned to the company in February 2022. In the meanwhile, Hendolin worked as Production Director at United Medix Laboratories Oy and Chief Technology Officer at Sulapac Oy. Hendolin has the degree of Ph.D. in molecular medicine.

CEO Jussi Hahtela: “I want to thank Minna Mäki for her contribution and significant role in R&D and in regulatory affairs. I wish her all the best in her future endeavors.”

Additional information:  Jussi Hahtela, CEO, Biohit Oyj, tel. +358 50 383 5948

investor.relations@biohit.fi www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Ämnen i artikeln


Biohit B

Senast

2,77

1 dag %

0,00%

1 dag

1 mån

1 år

Marknadsöversikt

OMX Stockholm 30

1 DAG %

−0,43%

Senast

2 517,96

1 mån
Loading market data...
Senaste aktieanalyserna på Placera
Kollage Analys Ny
Privatekonomi med Placeras expert
Karolina Palutko Macéus
Karolina Palutko Macéus skriver om allt som har med privatekonomi att göra och hur du kan få mer pengar i plånboken.
Affärsvärlden
AFV
Är du kund hos Avanza? Just nu kan du få en unik rabatt på Affärsvärlden. Afv har 28 år i rad utsetts till Sveriges bästa affärsmagasin i en undersökning med börs-VD:ar, finanschefer, IR-chefer och aktieproffs.
Annons
Introduce
för börsens små- och medelstora företag.
Annons
Investtech
Här hittar du våra artiklar om teknisk analys i samarbete med Investtech.